Treatment of the polycystic ovary syndrome with lifestyle intervention
- 1 December 2002
- journal article
- research article
- Published by Wolters Kluwer Health in Current Opinion in Endocrinology, Diabetes and Obesity
- Vol. 9 (6) , 459-468
- https://doi.org/10.1097/00060793-200212000-00004
Abstract
The polycystic ovary syndrome (PCOS) is a heterogeneous clinical entity defined as the association of hyperandrogenism with chronic anovulation in women without specific underlying disorders of the adrenal and pituitary glands. On the other hand, all features of the metabolic syndrome, particularly insulin resistance and associated hyperinsulinemia, are present in most women with PCOS. Insulin is a physiologic hormone regulating ovarian functions, specifically ovarian steroidogenesis. Hyperinsulinemia may therefore play a pivotal role in favoring the hyperandrogenic state and related clinical and metabolic alterations. In addition, as originally described by Stein and Leventhal (1), obesity is very common in women with PCOS, particularly the abdominal phenotype. There is consistent evidence that obese women with PCOS may be characterized by a different hormonal environment from that observed in their normal-weight counterparts. The main differences include more severe insulin resistance and hyperinsulinemia and a worsened hyperandrogenic state. Menstrual cyclicity and fertility rate are negatively affected by the presence of insulin resistance and hyperinsulinemia and may be further worsened in obese women with PCOS. Weight loss should represent the first-line approach in the treatment of these patients, because it significantly improves hormonal and metabolic abnormalities and may favor spontaneous ovulation and improve fertility rate in most of them. Individualized pharmacologic support aimed at favoring weight loss and maintenance and improving insulin resistance may play a complementary role in lifestyle interventional programs including dietary modifications and appropriate physical activity. Because of its proven effectiveness, this approach should therefore be widely extended in clinical practice. This, in fact, may ultimately be beneficial even in the prevention of diabetes type 2 and cardiovascular diseases, toward which women with PCOS appear to be susceptible.Keywords
This publication has 69 references indexed in Scilit:
- Insulin sensitivity, insulin secretion, and metabolic and hormonal parameters in healthy women and women with polycystic ovarian syndromeHuman Reproduction, 2000
- Insulin Resistance and the Polycystic Ovary Syndrome: Mechanism and Implications for PathogenesisEndocrine Reviews, 1997
- Fetal growth, length of gestation, and polycystic ovaries in adult lifeThe Lancet, 1997
- Cellular Insulin Resistance in Adipocytes from Obese Polycystic Ovary Syndrome Subjects Involves Adenosine Modulation of Insulin SensitivityJournal of Clinical Endocrinology & Metabolism, 1997
- Insulin, somatotropic, and luteinizing hormone axes in lean and obese women with polycystic ovary syndrome: common and distinct featuresJournal of Clinical Endocrinology & Metabolism, 1996
- Neuroendocrinology of the polycystic ovary syndromeBailliere's Clinical Endocrinology and Metabolism, 1996
- Beta-cell dysfunction independent of obesity and glucose intolerance in the polycystic ovary syndromeJournal of Clinical Endocrinology & Metabolism, 1996
- The independent effects of polycystic ovary syndrome and obesity on serum concentrations of gonadotrophins and sex steroids in premenopausal womenClinical Endocrinology, 1994
- The impact of obesity on hyperandrogenism and polycystic ovary syndrome in premenopausal women*Clinical Endocrinology, 1993
- Risk factors for coronary artery disease in lean and obese women with the polycystic ovary syndromeClinical Endocrinology, 1992